Servier Pharmaceuticals LLC drugs
4 results
Asparlas (calaspargase pegol)
(calaspargase pegol)Servier Pharmaceuticals LLC
Usage: ASPARLAS is indicated for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years, as part of a multi-agent chemotherapy regimen.
Oncaspar (pegaspargase)
(Pegaspargase)Servier Pharmaceuticals LLC
Usage: ONCASPAR® is indicated as part of a multi-agent chemotherapy regimen for the first-line treatment of pediatric and adult patients with acute lymphoblastic leukemia (ALL), including those with hypersensitivity to native L-asparaginase.
Tibsovo (ivosidenib)
(ivosidenib)Servier Pharmaceuticals LLC
Usage: TIBSOVO is indicated for treating newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in older adults or those with comorbidities, relapsed/refractory AML, relapsed/refractory myelodysplastic syndromes (MDS), and previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.
Voranigo (vorasidenib)
(vorasidenib)Servier Pharmaceuticals LLC
Usage: VORANIGO is indicated for treating adults and pediatric patients aged 12 and older with Grade 2 astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations, post-surgery (biopsy, sub-total, or gross total resection), as confirmed by an FDA-approved test.